Abstract
Objective: The objective of this study is to investigate the risk factors for developing postthymectomy myasthenic crisis in thymoma patients. Patients and Methods: Patients with thymoma received thymectomy from January 2001 to December 2014 were reviewed and included in this retrospective study in Lishui People's Hospital. Seventy-seven patients were included in this study. For the 77 cases, 66 patients not developing postthymectomy myasthenic crisis were considered as a control group, and other 11 subjects developing postthymectomy myasthenic were considered as the case group. The potential risk factors such age, gender, Osseman stage, Masaoka, pyridostigmine bromide, and et al. were compared between case and control group firstly by Chi-square test or Student's t-test and then by logistic regression test. Results: Eleven patients developed postthymectomy myasthenic with the incidence of 14.3%; logistic regression analysis indicates that pyridostigmine bromide >360 mg/day administration (OR = 21.2, P < 0.05), postsurgery pulmonary infection (OR = 8.3, P < 0.05) and myasthenic crisis prior surgery (OR = 3.2, P < 0.05) were the independent risk factors for developing postthymectomy myasthenic crisis in thymoma patients. Conclusion: Thymoma patients with a large dosage of pyridostigmine bromide administration, postsurgery pulmonary infection and myasthenic crisis prior surgery were easy to have postthymectomy myasthenic crisis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer